CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021
CTI BioPharma Corp. (NASDAQ: CTIC) will announce its first quarter 2021 financial results on June 1, 2021, after U.S. market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and provide a corporate update. Interested participants can join the call by dialing (877) 735-2860 domestically or (602) 563-8791 internationally, using conference ID 9343326. Additionally, a live audio webcast will be available on CTI's website, with a replay accessible for 30 days. CTI focuses on developing targeted therapies for blood-related cancers, primarily evaluating pacritinib.
- Scheduled announcement of Q1 2021 financial results shows transparency.
- Focus on developing pacritinib for blood-related cancers highlights commitment to addressing unmet medical needs.
- None.
SEATTLE, May 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).
To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 9343326. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-first-quarter-2021-financial-results-on-june-1-2021-301283960.html
SOURCE CTI BioPharma Corp.
FAQ
When will CTI BioPharma report its first quarter 2021 financial results?
What time is the conference call for CTI BioPharma's financial results?
How can I access the live audio webcast of CTI BioPharma's results?
What is the focus of CTI BioPharma's development efforts?
